- Home
- APRE
as 01-22-2025 12:31pm EST
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 15.8M | IPO Year: | 2019 |
| Target Price: | $15.50 | AVG Volume (30 days): | 33.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.15 - $8.85 | Next Earning Date: | 11-07-2024 |
| Revenue: | $1,310,839 | Revenue Growth: | 130.31% |
| Revenue Growth (this year): | 134.21% | Revenue Growth (next year): | -32.80% |
Latest Aprea Therapeutics Inc. Common stock News
APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Zacks
2 months ago
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
Simply Wall St.
2 months ago
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
2 months ago
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
2 months ago
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Zacks
3 months ago
Pacira (PCRX) Q3 Earnings Beat Estimates
TipRanks
3 months ago
Aprea Therapeutics presents preliminary results on APR-1051
Simply Wall St.
3 months ago
Insider Spends US$132k Buying More Shares In Aprea Therapeutics
Compare APRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APRE Aprea Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.